Utløst oppgang av artikkel finans avisen "Vi kunne vært verdt 100 ganger mer"


Skal det komme noe godt ut av gamle Targovax? Virker som denne er glemt i det siste. Nå kan gjennombruddet komme med ny vaksine.

Nå halvert seg siden emisjonen på 2.50 kr. Kan det fortsatt være noe igjen i Circio?

Oppdatert 24.oktober:

"Circio selected to present its circVec circular RNA expression platform at the
European Society of Cell and Gene Therapy (ESGCT) annual meeting in Rome 22-25
October; a prestigious and widely attended international gene therapy conference
· Circio presented new circVec protein expression data showing statistically
significant advantage vs. conventional mRNA-based vector expression both in
vitro and in vivo
· The circVec 2.1 generation shows 15x increase in protein expression in vivo,
and has the potential to substantially improve on the performance of current
gold-standard gene therapy approaches

Oslo, Norway 24 October 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces the publication of new, strong and statistically
significant circVec circular RNA in vivo expression proof-of-concept data,
presented both in the form of a poster and oral presentation by CTO, Dr. Thomas
B Hansen, at the European Society of Cell and Gene Therapy (ESGCT) annual
meeting 2024.

"Circio continues to build momentum with the unique and powerful circVec
platform. We selected the prestigious ESGCT meeting to present our latest
results as it provided a great opportunity to showcase our technology to a broad
life science industry and academic audience," said Dr. Thomas B. Hansen, CTO of
Circio. "circVec significantly outperforms mRNA-based expression both in vitro
and in vivo and has the potential to offer substantial enhancement over current
gold-standard gene therapy approaches."

In the ESGCT presentation, Circio showed the evolution and improvements of the
circVec platform from the initial circVec 1.0 design to the current generation
2.1. Long-term in vivo experiments have now demonstrated that circVec 2.1
robustly outperforms classical mRNA-based expression over time, offering
enhanced durability that reaches up to 15-fold higher reporter signals in mouse
models. Additionally, a machine-learning approach to codon optimization has
generated a novel circVec 2.2 design, delivering a further 2-4-fold increase in
protein yield.

Circio is currently testing the performance of circVec 2.1 and 2.2 in both viral
and DNA vector systems in multiple tissues and disease settings in vivo. These
data will guide future development and partnering strategy for the circVec
platform"